Using MRI to predict outcomes in pancreatic cancer
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients
This study is testing if a special type of MRI can help predict how well patients with pancreatic cancer will respond to their treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 36 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Cedars-Sinai Medical Center Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Los Angeles, California) |
| Trial ID | NCT04700488 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to evaluate the effectiveness of Six-Dimensional Magnetic Resonance Imaging (6D-MRI) in predicting treatment outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). The study focuses on assessing the tumor microenvironment, including factors like vascularity and fibrosis, to determine how well patients respond to neoadjuvant therapy. Participants will undergo multiple MRI sessions to gather data on their tumors and treatment responses.
Who should consider this trial
Good fit: Ideal candidates include patients with resectable or borderline resectable pancreatic cancer who are set to undergo neoadjuvant chemotherapy and can complete multiple MRI sessions.
Not a fit: Patients with previously treated PDAC, metastatic disease, or those unable to undergo MRI exams will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized treatment plans for patients with pancreatic cancer, improving their chances of successful outcomes.
How similar studies have performed: While the use of advanced MRI techniques in cancer assessment is gaining traction, this specific approach using 6D-MRI for PDAC outcomes prediction is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy * Patients able to undergo at least two sets of MRI sessions * Access to a device that has the capability to sync to the Fitbit (or access to a family member's, caregiver's, or friend's device) Exclusion Criteria: * Patients who have previously been treated for PDAC * Patients unable to undergo MRI exam w/contrast * Patients with metastatic pancreatic cancer visualized on index diagnostic imaging * Patients with certain metallic implants * Patients experiencing claustrophobia
Where this trial is running
Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California, United States (Recruiting)
Study contacts
- Principal investigator: Stephen Pandol, MD — Cedars-Sinai Medical Center
- Study coordinator: Liliana Bancila
- Email: Liliana.Bancila@cshs.org
- Phone: 310-423-3872
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.